India Inc. Intra nasal H1N1 Vaccine

Last week Saturday Pune based Serum institute of India launched VaxiFlu-S (purified A (H1N1) flu vaccine) indigenous vaccine in New Delhi, This vaccine will be available in the Indian market within next 10 days, and last year Pune had been the epicenter for Swine flu, hope this year it will have enough resources to fight.

For more read the following link

http://www.thehindu.com/news/national/article487465.ece

India Biogeneric.........for double digit dollar revenue

One of the largest generic manufacturer of India Inc Cipla is planning to launch its own line of Bio similar products, in a press release Cipla's chairman Yusuf Hamied said that he plans to invest in companies in India and Hong Kong who will be able to produce so-called monoclonal antibodies. The technology will enable Mumbai-based Cipla to have access to products modelled bio equivalence to Roche’s Avastin, Herceptin cancer drugs and Amgen’s rheumatoid arthritis treatment Enbrel.

PS: Cipla is the largest supplier of HIV drugs:)

Link:http://www.businessweek.com/news/2010-06-16/cipla-targets-19-billion-a-year-roche-amgen-drugs-update2-.html

Europe's Big Daddies for Active M&A

Last year after the present Sanofi's new CEO joined the board from GSK, Sanofi has been aggressively into Mergers and Acquisitions, now another big giant to look for is Bayer for long time Bayer has been into active patent portfolio management and out licensing but as we have new CEO on board we have many mergers and acquisition awaiting from Bayer's end.
....................................................................................
Yesterday I was reading some analyst report in which they have mentioned about some companies for which venture capitalists have high hopes, they include the following

-RXi Pharmaceuticals Corporation (Nasdaq: RXII): RXi's proprietary sd-rxRNA molecules has a unique 'self delivery' property.
-Northwest Bio therapeutics (OTC BB: NWBO.OB): Northwest Bio therapeutics' vaccine to combat brain cancer
-Dendreon Corporation's (NASDAQ: DNDN): Dendreon announced recently that their drug Provenge for treatment for prostate cancer has been approved by FDA.

Sanofi deal Update -2010-Q2

In my last article I had mentioned about Sanofi Aventis generic market penetration in emerging markets, today morning the news was that Sanofi is interested in venturing into Ophthalmology domain and in the news it was also mentioned that last year as it had closed 33 deals it is going to close the same number of deals by this year end......An interesting observation is that last year Abbott was the company which had invested heavily in Ophthalmology segment but this year with Sanofi eyeing this therapeutic landscape we will have tough neck to neck competition between the two giants in Ophthalmology therapy landscape in the coming decade.

Read more in http://www.forexyard.com/en/news/Sanofi-RD-sets-sight-on-eye-diseases-2010-06-03T081726Z-INTERVIEW

Sanofi Aventis-Update

Last year in my blog I had mentioned something about Sanofi aventis penetration into emerging markets which include Latin American countries, India and China. For instance in Latin America it went into Merger and Acquisition of generic, India in similar way for acquisition of Shanta Biotech Hyderabad based Bio similar company and in China it went into to open its R&D centre for Biologics and generic production and now last week in a press release it was mentioned that Sanofi Aventis in going to invest around 5 Billion Yen in Japanese generic company Nichi- Iko Pharmaceutical.........now I guess next thing is that the company will try to strategize its marketing in South Asia..................